Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1

• Published in: Oncotarget 2016-08, Vol.7 (35), p.57213-57227
• Main Authors: Cha, Byong-Ki, Kim, Young-Suk, Hwang, Ki-Eun, Cho, Kyung-Hwa, Oh, Seon-Hee, Kim, Byoung-Ryun, Jun, Hong-Young, Yoon, Kwon-Ha, Jeong, Eun-Taik, Kim, Hak-Ryul
• Format: Article
• Language: English
• Subjects: A549 Cells; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Anti-Inflammatory Agents, Non-Steroidal - pharmacology; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Celecoxib - administration & dosage; Celecoxib - pharmacology; Cell Line, Tumor; Cell Movement - drug effects; Down-Regulation; Epithelial-Mesenchymal Transition - drug effects; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Neoplasm Invasiveness; Research Paper; Sirtuin 1 - metabolism; Sulindac - administration & dosage; Sulindac - pharmacology; Transforming Growth Factor beta1 - antagonists & inhibitors
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.11127

The non-steroidal anti-inflammatory drugs (NSAIDs) celecoxib and sulindac have been reported to suppress lung cancer migration and invasion. The class III deacetylase sirtuin 1 (SIRT1) possesses both pro- and anticarcinogenic properties. However, its role in inhibition of lung cancer cell epithelial-mesenchymal transition (EMT) by NSAIDs is not clearly known. We attempted to investigate the potential use of NSAIDs as inhibitors of TGF-β1-induced EMT in A549 cells, and the underlying mechanisms of suppression of lung cancer migration and invasion by celecoxib and sulindac. We demonstrated that celecoxib and sulindac were effective in preventing TGF-β1-induced EMT, as indicated by upregulation of the epithelial marker, E-cadherin, and downregulation of mesenchymal markers and transcription factors. Moreover, celecoxib and sulindac could inhibit TGF-β1-enhanced migration and invasion of A549 cells. SIRT1 downregulation enhanced the reversal of TGF-β1-induced EMT by celecoxib or sulindac. In contrast, SIRT1 upregulation promoted TGF-β1-induced EMT. Taken together, these results indicate that celecoxib and sulindac can inhibit TGF-β1-induced EMT and suppress lung cancer cell migration and invasion via downregulation of SIRT1. Our findings implicate overexpressed SIRT1 as a potential therapeutic target to reverse TGF-β1-induced EMT and to prevent lung cancer cell migration and invasion.